Medication info

Empagliflozin 10 mg Tablets

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tablet
Manufacturer / importer
White Life Sciences Co., Ltd.
Appearance
Light yellow, round film-coated tablets
Packaging
30 tablets/PTP (10 tablets/PTP × 3), 10 tablets/PTP (10 tablets/PTP × 1)
Approval status
Active

MFDS item code 202106162 · Approved 2021.08.25

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent eGFR of less than 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the eGFR decreases to less than 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those receiving dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited.

Ingredients

Manufacturer
White Life Sciences Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
View approved original text

This medicine is used in conjunction with dietary and exercise therapy to improve blood sugar control in adult patients with type 2 diabetes. It can be administered as monotherapy or in combination with other medications. Particularly, it should be used under the guidance of a specialist for patients with type 2 diabetes who have cardiovascular disease and for whom blood sugar is not adequately controlled. This medicine helps prevent diabetes-related complications and improve patient health by assisting with blood sugar management.

How to take

Adult dose

The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent eGFR of less than 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the eGFR decreases to less than 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those receiving dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited.

Precautions

This medicine should not be used in patients with allergic reactions to the active ingredient or any component. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. It is not used in patients with severely impaired kidney function, particularly those with a glomerular filtration rate below 30 mL/min/1.73m2 or in patients with end-stage renal disease or undergoing dialysis. Additionally, this medicine contains lactose and should not be administered to patients with metabolic disorders such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption. Patients with renal impairment should be closely monitored for kidney function when using this medicine, and if the glomerular filtration rate is below 60 mL/min/1.73m2, dosage adjustment or discontinuation should be considered. In patients with heart failure classified as NYHA class III-IV, its use is not recommended, and it should be used with caution in class I-II patients. When used in combination with insulin or sulfonylureas, there may be an increased risk of hypoglycemia, requiring dosage adjustments. This medicine has been reported to cause primarily hypoglycemia, genital infections, increased urination, urinary tract infections, decreased fluid volume, increased blood creatinine levels, and other adverse reactions. Severe metabolic abnormalities such as ketoacidosis may occur; therefore, treatment should be stopped immediately if related symptoms appear and a medical evaluation should be sought. Elderly patients, especially those over 75 years old, are at higher risk for fluid loss; therefore, caution is needed and physical status should be closely monitored in situations that may cause fluid volume loss. This medicine may increase the risk of serious urinary infections, such as urosepsis and pyelonephritis, so prompt treatment is necessary if there are signs of infection. There may also be an increased risk of genital fungal infections, so monitoring and appropriate treatment are required. A positive reaction may appear on urine glucose tests, which should be taken into consideration. Caution is required when driving or operating machinery due to the risk of hypoglycemia, especially when taken with insulin or sulfonylureas. It should be avoided during pregnancy, and treatment should be discontinued immediately upon confirmation of pregnancy. For breastfeeding, it is recommended to discontinue breastfeeding as this medicine may be excreted in breast milk. The safety and effectiveness of this medicine in children, i.e., patients under 18 years of age, have not been established; therefore, it should not be used. No specific toxic symptoms have been reported in cases of overdose, but appropriate treatment based on clinical condition is necessary. This medicine should be kept out of reach of children, and transferring it to another container should be avoided.

Side effects

  • Hypoglycemia
  • vulvovaginitis
  • balanitis
  • other genital infections
  • urinary tract infections
  • perineal necrosis
  • ketoacidosis
  • pruritus
  • rash
  • urticaria
Show 12 more
  • angioedema
  • decreased fluid volume
  • increased urination
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased blood creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is also advisable to store it at room temperature, avoiding extremes of cold or hot, with a temperature maintained between 1 degree and 30 degrees.

Appearance and packaging

Appearance

Light yellow, round film-coated tablets

Package unit

30 tablets/PTP (10 tablets/PTP × 3), 10 tablets/PTP (10 tablets/PTP × 1)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.